http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Otsuka to Host Web Briefing on Tolvaptan Phase 3 Trial Results in Polycystic Kidney Disease
-
Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
-
Otsuka and Lundbeck to Showcase Safety and Efficacy Data in Treatments for Challenging Mental Health Conditions
-
ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
-
Otsuka and Proteus Digital Health® Resubmit Application to FDA for First Digital Medicine
-
Otsuka Announces Results of Phase 3 Data on Tolvaptan
-
Launch of Alzheimer’s Journey Coordinator Certificate Program™
-
Otsuka and Lundbeck Announce Results of Brexpiprazole on Symptoms of Agitation Related to Alzheimer’s-Type Dementia
-
Otsuka Pharmaceutical to Acquire Neurovance, Inc.
-
U.S. FDA Approves Otsuka and Lundbeck’s REXULTI® (Brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
-
Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in American Journal of Psychiatry

